Supplementary Materials

Supplementary Material for:

Nigral dopaminergic PAK4 prevents neurodegeneration in rat models of Parkinson's disease

So-Yoon Won, Mee-Hee Park, Soon-Tae You, Seung-Won Choi, Hyong-Kyu Kim, Catriona McLean, Suk-Chul Bae, Sang Ryong Kim, Byung Kwan Jin, Kun Ho Lee, Eun-Young Shin, Eung-Gook Kim*

*Corresponding author. Email: egkim{at}chungbuk.ac.kr

Published 30 November 2016, Sci. Transl. Med. 8, 367ra170 (2016)
DOI: 10.1126/scitranslmed.aaf1629

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Confirmation of the specificity of the anti-pPAK4 antibody.
  • Fig. S2. Immunohistochemical analysis of PAK5 and PAK6 in nigral dopamine neurons.
  • Fig. S3. Representative images of costaining for pPAK4/Bcl-2 and pPAK4/TUNEL in the brains of PD patients.
  • Fig. S4. Monitoring lentivirus-mediated delivery of PAK4 shRNA into the rat SN.
  • Fig. S5. Exclusion of the off-target effects of rat PAK4 shRNA.
  • Fig. S6. PF-3758309 sensitizes rats to 6-OHDA–induced neurotoxicity.
  • Fig. S7. caPAK4 and WT PAK4 protect SH-SY5Y cells against 6-OHDA–induced toxicity.
  • Fig. S8. Monitoring lentivirus-mediated delivery of caPAK4 into the rat SN.
  • Fig. S9. Monitoring the expression of human α-synuclein in the rat striatum and SN.
  • Fig. S10. caPAK4 requires CREB and CRTC1 for neuroprotection.
  • Fig. S11. Identification of S215 of CRTC1 as a major phosphorylation site.
  • Table S1. Summary of parameters for experimental groups.
  • Table S2. Immunohistochemical analysis of neuromelanin-positive cells in human PD.
  • References (6267)

[Download PDF]